3. Ariad Pharmaceuticals (ARIA)
Company Profile: Ariad Pharmaceuticals develops cancer treatments by regulating cell signaling with small molecules.Share Price: $4.57 (Dec. 17) 2010 Stock Performance: 100% Analyst Consensus: Nine researchers say investors should buy shares of Ariad Pharmaceuticals. There is one analyst with a "hold" rating on Ariad. No firm has a "sell" rating on the stock. Bullish Case: Brean Murray Carret analyst Ling Wing reiterated a "buy" rating on Ariad in a Dec. 6 research report, based on expectations of Phase III trial data for ridaforolimus, which is Ariad's drug candidate to treat patients with advanced sarcomas. "Near term, we expect partner Merck (MRK) to report the final analysis from the Phase III trial of ridaforolimus in advanced sarcoma patients in early [first quarter of 2011]," Wang wrote. "Although we have reservations in the outcome of this trial, we view the risk/reward at current levels to be favorable, especially with Merck taking full financial responsibility of the program."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV